J
Jill M. Fritz
Researcher at National Institutes of Health
Publications - 10
Citations - 2548
Jill M. Fritz is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Unfolded protein response & Immune dysregulation. The author has an hindex of 9, co-authored 10 publications receiving 1137 citations. Previous affiliations of Jill M. Fritz include Cincinnati Children's Hospital Medical Center.
Papers
More filters
Journal ArticleDOI
A guide to cancer immunotherapy: from T cell basic science to clinical practice.
TL;DR: This guide to cancer immunotherapy provides a comprehensive historical and biological perspective regarding the advent and clinical implementation of cancer immunotherapeutics, with an emphasis on the fundamental importance of T lymphocyte regulation.
Journal ArticleDOI
Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy
Bernice Lo,Kejian Zhang,Wei Lu,Lixin Zheng,Qian Zhang,Chrysi Kanellopoulou,Yu Zhang,Zhiduo Liu,Jill M. Fritz,Rebecca A. Marsh,Ammar Husami,Diane Kissell,Shannon Nortman,Vijaya Chaturvedi,Hilary Haines,Lisa R. Young,Jun Mo,Alexandra H. Filipovich,Jack J. Bleesing,Peter Mustillo,Michael C. Stephens,Cesar M. Rueda,Claire A. Chougnet,Kasper Hoebe,Joshua J McElwee,Jason D. Hughes,Elif Karakoc-Aydiner,Helen F. Matthews,Susan Price,Helen C. Su,V. Koneti Rao,Michael J. Lenardo,Michael B. Jordan +32 more
TL;DR: Patients with an autoimmune disorder caused by deficiency of a protein called LRBA responded dramatically to the drug abatacept, a CTLA4 (cytotoxic T lymphocyte antigen-4)–immunoglobulin fusion drug, and the relationship between the two proteins was revealed: LRBA controls the intracellular trafficking and degradation ofCTLA4.
Journal ArticleDOI
Development of immune checkpoint therapy for cancer
Jill M. Fritz,Michael J. Lenardo +1 more
TL;DR: Fritz and Lenardo discuss the basic science and clinical discoveries of immune checkpoint blockade, which boosts antitumor immunity and increases survival of patients with cancer.
Journal ArticleDOI
CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency
TL;DR: Here, a review of patients with immune dysregulation and lymphoproliferative disease resulting from 2 different genetic diseases and CTLA-4 blockade therapy is reviewed, emphasizing the crucial role of CTla-4 in immune checkpoint regulation.
Journal ArticleDOI
Deficiency of the BiP cochaperone ERdj4 causes constitutive endoplasmic reticulum stress and metabolic defects
Jill M. Fritz,Mei Dong,Karen S. Apsley,Emily P. Martin,Cheng-Lun Na,Sneha Sitaraman,Timothy E. Weaver +6 more
TL;DR: Findings indicate that the chaperone activity of ERdj4 is important for ER homeostasis in vivo.